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The plasminogen activator system has been recognized to play 
an important role in tumour growth and metastasis (Dano et al,
1985; Kwaan, 1992; Andreasen et al, 1997). Urokinase-type
plasminogen activator (uPA) has an adverse effect on cancer as
supported by in vitro and in vivo experiments showing that a high
content of uPA is mitogenic, mediates pericellular proteolysis
promoting tumour cell invasion and enhances angiogenesis. PAI-1
was also found to be a bad prognostic factor in a number of
tumours, including carcinoma of the breast, lung, colon, ovarian,
gastric and kidney (Grondahl-Hansen et al, 1993; Janicke et al,
1993; Bashar et al, 1994; Casslen et al, 1994; Foekens et al, 1994;
Kobayashi et al, 1994; Kuhn et al, 1994; Nekarda et al, 1994;
Pedersen et al, 1994; Sier et al, 1994; Hofmann et al, 1996;
Sugiura et al, 1999). However, when human prostate carcinoma
PC-3 cells were transfected with plasminogen activator inhibitor 1
(PAI-1) gene, there was a decrease in primary tumour size and
decreased metastasis in vivo (Soff et al, 1995). These conflicting
results have not been fully explained. A possible explanation for
this apparent controversy may be related to the source of PAI-1.
Studies in which PAI-1 levels were correlated with a bad prognosis
involved the evaluation of PAI-1 levels in the host, such as in
surgical specimens (Foekens et al, 1994; Kuhn et al, 1994;
Pedersen et al, 1994; Sier et al, 1994; Hofmann et al, 1996;
Sugiura et al, 1999) or in patient’s plasma (Bashar et al, 1994;
Casslen et al, 1994). In contrast, when the PAI-1 level is increased
in tumour cells as a result of transfection, the tumour invasiveness
and metastatic potential is decreased (Cajot et al, 1990; Alizadeh
et al, 1995; Soff et al, 1995). In this paper, we provide data to
support the possibility that the addition of PAI-1 to tumour cells in
culture, acting as increased host PAI-1, inhibits apoptosis of the
tumour cells. Furthermore, this novel action of PAI-1 was also
observed when PAI-1 is added to non-tumoural cells in culture.
MATERIALS AND METHODS
Reagents
A stable variant of PAI-1 (PAI-1-stab), recombinant wild-type
PAI-1 (PAI-1-wt) and latent PAI-1 (PAI-1-lat) were produced as
described previously (Gils et al, 1996; Vleugels et al, 1998). The
stable variant, containing point mutations of N150H, K154T,
Q301P, Q319L and M354L, does not undergo conformational
changes into the latent form (Vleugels et al, 1998). A specific
monoclonal antibody with neutralizing properties towards PAI-1
activity, MA-33B8, and a monoclonal antibody against PAI-1 but
not interfering with the activity, MA-19A5, were produced as
described (Debrock and Declerck, 1997).
Recombinant two-chain uPA was provided by Dr Jack Henkin
of Abbott Laboratories (Abbott Park, IL, USA). The complex of
uPA/PAI-1 was prepared by incubating equimolar amounts of uPA
and PAI-1 at 37°C for 30 min. This complex forms a lytic band of
MW 110 kDa on zymography (Levenson et al, 1998).
Anti-human Fas mouse monoclonal IgM clone CH11 was
purchased from Immunotech (Westbrook, ME, USA). Antibodies
against domain 1 or domain 2 of uPA receptor were purchased
from American Diagnostica Inc. (Greenwich, CT, USA).
Camptothecin (CPT) and etoposide (VP16) and all the other chem-
icals were purchased from Sigma Chemical Co. (St Louis, MO,
USA).
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The human prostate carcinoma line PC-3 was originally obtained
from Dr James Kozlowski of Northwestern University (Chicago,
IL, USA). The human promyelocytic leukaemia cell line HL-60
was purchased from American Type Culture Collection (Rockville,
MD, USA). PC-3 or HL-60 cells were maintained in RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS), 
2 mmol 1–1 L-glutamine, 2.5 mg ml–1 amphotericin B, 100 IU ml–1
penicillin and 100 mg ml–1 streptomycin in 5% carbon dioxide
(CO2) at 37°C. The benign human breast epithelial cell line MCF-
10A was obtained from Dr Sigmund Weitzman of Northwestern
University (Chicago, IL, USA). MCF-10A cells were cultured in
Dulbecco’s modified Eagles medium (DMEM)/F12 medium (Life
Technologies, Inc.) supplemented with 5% horse serum, 2 mmol 1–1
L-glutamine, 2.5 mg ml–1 amphotericin B, 100 IU ml–1 penicillin,
100 mg ml–1 streptomycin, 10 mg ml–1 insulin, 100 ng ml–1 cholera
toxin, 0.5 mg ml–1 hydrocortisone and 20 ng ml–1 epidermal growth
factor in 5% CO2 at 37°C. A primary culture of human umbilical
vein endothelial cells (HUVEC) was provided by Dr H William
Schnaper of Northwestern University (Chicago, IL, USA). The
primary HUVEC (passage 5) were maintained in RPMI-1640
medium supplemented with 10% BCS, 2 mmol 1–1 L-glutamine, 
2.5 mg ml–1 amphotericin B, 100 IU ml–1 penicillin, 100 mg ml–1
streptomycin, 50 mg ml–1 gentamicin, 5 U ml–1 sodium heparin 
and 0.16 mg ml–1 endothelial cell growth supplement in 5% CO2 at
37°C.
Induction of apoptosis
HL-60 and PC-3 cells
Exponentially growing HL-60 or PC-3 cells that were approxi-
mately 60% confluent were exposed to 0.15 mmol l–1 of CPT or 
50 mmol l–1 of VP16 to induce apoptosis. HL-60 cells were treated
with CPT for 2 h. PC-3 cells were treated with CPT for 24 h or
with VP16 for 72 h. Then the cells were harvested and analysed
for percentage of cells undergoing apoptosis.
MCF-10A cells
These cells were treated with 0.5 mg ml–1 anti-Fas antibody clone
CH11 for 48 h. An irrelevant mouse IgM antibody was used as a
negative control.
HUVEC
These cells were kept in culture medium without serum, heparin
and growth factor for 16 h.
Identification of apoptosis with annexin V-propidium
iodide staining
Annexin V and propidium iodide (PI) staining was performed
according to the protocol of apoptosis detection kit from R&D
Systems (Minneapolis, MN, USA). Briefly, cells were rinsed once
with phosphate-buffered saline (PBS) and then resuspended in
onefold binding buffer. Then, 1 ´ 105 cells in 100 ml were incubated
with 10 ml of fluorescein-conjugated annexin V and 10 ml of PI in
the dark for 10 min at room temperature. The cells then were
pelleted in a microcentrifuge, resuspended in 30 ml of onefold
binding buffer and smeared on slides. Cells were counted under a
fluorescent microscope. Total cell counts were taken under tung-
sten light while the annexin V-positive (green indicating early
apoptosis) and the annexin V and PI-positive cells (green and red,
indicating late apoptosis) were taken under ultraviolet light. In each
slide, 200–300 cells were counted. The number of stained cells was
divided by the total cell number to determine the per cent apoptosis.
The per cent apoptosis as described in this study includes both early
and late apoptotic cells in the calculation. PAI-1 has been shown to
have the same effect on early and late apoptosis. Also, we calcu-
lated the percent inhibition by PAI-1 using the following formula:
TdT-mediated DNA nick end labelling with fluorescein-
dUTP and flow cytometry assay
The protocol was adapted from apoptosis detection system of
Promega (Madison, WI, USA). Briefly, 3 ´ 106 cells were washed
with PBS, fixed with 1% formaldehyde for 20 min on ice and then
stored in 70% ethanol at –20°C for at least 4 h. After they were
incubated in equilibration buffer for 5 min at room temperature, 
2 ´ 106 cells were labelled at 37°C in the dark for 1 h with terminal
deoxynucleotidyl transferase (TdT) incubation buffer containing
TdT enzyme and fluorescein-dUTP. The reaction was terminated
by adding 20 mmol l–1 EDTA. The cells were then stained for 
30 min with PI solution containing 5 mg ml–1 PI and 50 mg ml–1
RNase. The cells were analysed with a Coulter flow cytometer.
Subsequently, the green fluorescence of fluorescein-dUTP and 
red fluorescence of PI were measured at 520 nm and 620 nm
respectively.
DNA fragmentation analysis
Genomic DNA was extracted using easy-DNA kit from Invitrogen
(San Diego, CA, USA). In brief, 107 cells were fixed in 70%
ethanol overnight and then resuspended in 200 ml PBS buffer.
After the cells were lysed with Solution A, nucleosomal DNA was
isolated with Solution B and chloroform and precipitated by
adding 100% ethanol. The pellet after centrifugation was rinsed
with 80% ethanol and resuspended in TE buffer. The RNA in the
solution was degraded by incubation with 40 mg ml–1 RNase at
37°C for 30 min. The amount of DNA was measured on a spec-
trophotometer at 260 nm, and the purity of DNA was determined
by an absorbance ratio of greater than 1.8 between 260 nm and 280
nm. Equal amounts of DNA (40 mg) and 10 ml low molecular
weight DNA marker (Bio-Rad, Hercules, CA, USA) were loaded
on a 2% agarose gel and electrophoresis for 2 h. The gel was
stained with ethidium bromide. The DNA laddering was visual-
ized by UV transillumination.
PAI-1 activity assay
PAI-1 activity assay was assayed with a Spectrolyse™ tPA/PAI
activity assay kit from American Diagnostica Inc. (Greenwich, CT,
USA). Briefly, the conditioned media was incubated with tPA stan-
dard for 15 min to allow the tPA-PAI-1 reaction. Then acetate
buffer was added and incubated at 37°C for 15 min to destroy 
a2-antiplasmin. The remaining tPA activity in the solution was
assayed in a 96-well plate. In each well, 10 ml solution was mixed
with 250 ml tissue activator reagent containing 0.04 mg ml–1
plasminogen and 0.4 mmol l–1 chromogenic plasmin substrate
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% apoptotic cells without PAI-1 – % apoptotic cells with PAI-1 ´ 100
% apoptotic cells without PAI-1 Spectrolyse™ PL in Tris buffer. Then, 10 ml fibrin stimulator
Desafib™ were added to accelerate the reaction. After incubation
at 37°C for 75 min, the reaction was stopped by mixing with 25 ml
stop solution. Absorbance at 405 nm was assayed with a plate
reader. The PAI-1 activity in the conditioned media was calculated
according to the remaining tPA activity in the solution determined
with tPA standard curve.
Statistical analysis
All the results represent mean value ± standard deviation.
Differences in mean values were analysed using Student’s t-test. P-
values > 0.05 were considered to be of no statistical significance.
RESULTS
Effect of PAI-1 on spontaneous and induced apoptosis
HL-60 cells were cultured for 4 h to determine the per cent of
spontaneous apoptosis, 12 ± 3.2. When 20 ng ml–1 of PAI-1-stab
was added, the per cent of apoptosis dropped to 7.3 ± 1.8 
(P < 0.005). When HL-60 cells were cultured with 0.15 mmol l–1
CPT for 4 h, the induced rate of apoptosis was 53 ± 7.9. PAI-1-stab
was also able to significantly (P < 0.005) inhibit the CPT-induced
apoptosis to 24 ± 5.8 when it was added concurrently with CPT. To
insure that the PAI-1-stab was acting on the cells and not directly
on the CPT to inhibit apoptosis, HL-60 was first treated with and
without CPT for 2 h and then washed. Then 20 ng ml–1 of PAI-1-
stab were added and the cells were further incubated for 2 h.
Figure 1 shows that PAI-1-stab is able to significantly reduce both
spontaneous and CPT-induced apoptosis in these cells (P < 0.001).
Also, PAI-1-stab is able to inhibit apoptosis in a dose-responsive
manner as illustrated in Figure 2. As the concentration of PAI-1-
stab was increased, the per cent inhibition increased.
PAI-1-stab can also inhibit apoptosis in PC-3 cells. As seen in
Figure 3A, PAI-1-stab significantly reduces the spontaneous and
CPT-induced apoptosis for these cells after 24 h of treatment 
(P < 0.001). When these cells are treated with etoposide (VP16)
for 72 h to induce apoptosis, a similar effect of PAI-1-stab was
found as shown in Figure 3B (P < 0.05).
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Figure 1 PAI-1-stab inhibited spontaneous and CPT-induced apoptosis in
HL-60 cells. HL-60 cells were treated with or without 0.15 mmol l–1 CPT for 
2 h, washed and then treated with 20 ng ml–1 of PAI-1-stab for 2 h. There was
a significant difference between cells with and without PAI-1 treatment for
spontaneous and induced apoptosis respectively (*P < 0.001)
Figure 2 PAI-1-stab inhibited apoptosis in a dose-responsive manner in
HL-60 cells. The percent inhibition of spontaneous apoptosis or CPT-induced
apoptosis was determined as shown in Materials and Methods, n = 3
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Figure 3 PAI-1-stab inhibited spontaneous and induced apoptosis in PC-3 cells. (A) PC-3 cells were treated with 0.15 mmol l–1 CPT and 20 ng ml–1 PAI-1-stab
concurrently for 24 h. There was a significant difference between the cells with and without PAI-1 treatment for spontaneous and CPT-induced apoptosis
respectively (*P < 0.001, n = 7). (B) PC-3 cells were treated with 50 mmol l–1 VP16 and 20 ng ml–1 PAI-1-stab concurrently for 72 h. There was a significant
difference between the cells with and without PAI-1 treatment for spontaneous and VP16-induced apoptosis respectively (**P < 0.05, n = 3)Likewise, PAI-1-stab was found to inhibit apoptosis in HUVEC
and MCF-10A (P < 0.05), while the latent form of PAI-1 did not (P
> 0.05, Figure 4).
The apoptosis-inhibiting effect of PAI-1-stab was verified by
DNA fragmentation analysis (Figure 5). We also found that 
20 ng ml–1 of PAI-1-stab could partially inhibit DNA laddering in
apoptotic cells, while PAI-1-stab in 2000 ng ml–1 had a greater
effect. Supporting data were obtained using the TdT (TUNEL)
method to stain HL-60 cells and analyse them with flow cytom-
etry (Figure 6).
The domain of PAI-1 responsible for inhibition of
apoptosis
PAI-1-wt was also tested for its effect on apoptosis. PAI-1-wt
could significantly inhibit spontaneous (P < 0.001) and CPT-
induced (P < 0.002) apoptosis in HL-60 cells. However, PAI-1-lat
did not show any significant inhibition. The inhibition by PAI-1-wt
was less than that of PAI-1-stab (Figure 7). To investigate this
reduced effect of PAI-1-wt, a chromogenic functional activity
assay was performed. The ability of PAI-1-stab to inhibit tPA
activity is approximately twofold that of PAI-1-wt in the same
concentration. After a 2-h incubation with HL-60 cells, the activity
of PAI-1-wt decreased while the activity of PAI-1-stab remained
the same (data not shown). It has been reported that the half-life of
the PAI-1-wt is approximately 2 h while the half life for PAI-1-stab
is 145 h (Vleugels et al, 1998). These data suggests that only the
active form of PAI-1 has an apoptosis-inhibiting function.
When a specific monoclonal antibody to PAI-1, MA-33B8, was
added to HL-60 cells concurrently with PAI-1-stab, the apoptosis-
inhibiting function of PAI-1-stab was effectively blocked. This
PAI-1 neutralizing monoclonal antibody, MA-33B8, acted in a
dose-responsive manner, but a non-neutralizing antibody MA-
19A5 had no such action (Figure 8). It has been suggested that MA-
33B8 inactivates PAI-1-stab through acceleration of the conversion
of the active conformation to the latent conformation (Vleugels et
al, 1998; Verhamme et al, 1999). Thus the reactive site loop in PAI-
1 may be responsible for the apoptosis-inhibiting function.
The role of uPA receptor in the inhibition of apoptosis
by PAI-1
To investigate the pathway by which PAI-1 inhibits apoptosis, the
possible role of PAI-1 interaction with the uPA receptor (uPAR)
was studied. One possible pathway is that PAI-1 inhibits apoptosis
by binding to uPA and forming a complex. This complex then binds
to domain 1 of uPAR. Figure 9A shows that the uPA/PAI-1-stab
Effect of PAI-1 on apoptosis 1705
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Figure 4 (A) Serum deprivation-induced apoptosis in HUVEC, was inhibited
by PAI-1-stab in concentrations of 200 ng ml–1 and 2000 ng ml–1 (*P < 0.05, 
n = 3), while latent PAI-1 in the same concentrations has no effect (P > 0.05,
n = 3). (B) Apoptosis was induced in the benign breast epithelial cell (MCF-
10A) by 0.5 mg ml–1 anti-Fas antibody for 48 h. PAI-1-stab was also able to
inhibit the apoptosis (*P < 0.05, n = 3), while latent PAI-1 has no effect 
(P > 0.05, n = 3)
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complex has no effect on spontaneous or on CPT-induced apoptosis
in HL-60 cells. This suggests, first, that PAI-1 is not inhibiting
apoptosis through binding uPA and then signalling through domain
1 of the uPAR. This is confirmed by the findings that the mono-
clonal antibody to domain 1 also had no effect on the apoptosis-
inhibiting action of PAI-1 (Figure 9B).
Since vitronectin can bind to domain 2 of the uPAR, a mono-
clonal antibody to domain 2 was used to block this signal trans-
duction pathway. The antibody did not block the function of
PAI-1-stab, which suggested that PAI-1-stab did not act through
binding vitronectin and then signalling through domain 2 of uPAR
to inhibit apoptosis (Figure 9B).
DISCUSSION
Tumour growth involves both cell proliferation and cell death, the
latter achieved mainly through the process of apoptosis. Although
the relationship between apoptosis and the plasminogen activator
system is not known, our present findings showed that PAI-1 could
inhibit both spontaneous and induced apoptosis in tumour cells.
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Figure 8 The effect of monoclonal antibodies on the ability of PAI-1-stab to inhibit (A) spontaneous and (B) CPT-induced apoptosis in HL-60 cells. A PAI-1
neutralizing antibody MA-33B8 or a non-neutralizing antibody MA-19A5 was added concurrently with 20 ng ml–1 PAI-1-stab for 2 h, n = 3It has been found that PAI-1 plays an important role in migration
and metastasis of tumour cells. PAI-1 may promote tumour cells
invasion by regulating uPAR-dependent cell adhesion (Deng et al,
1996; Waltz et al, 1997). On the other hand, PAI-1 may inhibit
integrin- and vitronectin-mediated cell migration by blocking avb3
binding to vitronectin (Stefansson and Lawrence, 1996; Kjoller et
al, 1997). Recently Bajou et al (1998) demonstrated that deficient
PAI-1 expression in host mice prevented cancer invasion and
vascularization.
PAI-1, the principal inhibitor of tPA and uPA, is produced by
hepatocytes, endothelial cells and many tumour cells. When first
secreted by cells, it is in an active form, but readily undergoes a
conformational change into the non-reactive latent form (Sancho et
al, 1995; Egelund et al, 1997). In the present study, a stable variant
of recombinant PAI-1 was able to significantly inhibit apoptosis in
HL-60 and PC-3 cells. In addition, when PAI-1-wt was added to
HL-60 cells, it could inhibit apoptosis as well. In contrast, the latent
form was found to have no inhibitory effect on apoptosis.
A specific neutralizing monoclonal antibody was previously
shown to accelerate conformational changes of PAI-1 resulting 
in loss of plasminogen activator inhibitory function of PAI-1
(Debrock and Declerck, 1997). The apoptosis-inhibiting function
of PAI-1 can also be effectively blocked with this antibody. This
provided additional evidence that only the active form of PAI-1
could inhibit apoptosis. Further support comes from our finding
that the uPA/PAI-1 complex could not inhibit apoptosis. These
data suggest that the reactive site loop in the PAI-1 molecule may
be responsible for the apoptosis-inhibiting function.
The pathway by which PAI-1 signals the cell to inhibit apoptosis
is not clear. One possibility is through uPAR, which is well
expressed in both HL-60 and PC-3 cells. uPA is a ligand to domain
1 of this receptor and was found in the present study not to inhibit
apoptosis. In fact, with amounts of uPA of 500 ng per 106 cells,
apoptosis was found to be enhanced to a small degree (data not
shown). Domain 1 of uPAR was ruled out as a possible pathway
for the action of PAI-1 because the uPA/PAI-1 complex could not
inhibit apoptosis, and antibody to domain 1 did not block the
action of PAI-1. Since vitronectin can also act as a ligand of uPAR
by binding to domain 2 (Wei et al, 1994; Kanse et al, 1996), a
monoclonal antibody to domain 2 was used to investigate the
function of domain 2 in uPAR. It had no effect on the apoptosis-
inhibitory effect of PAI-1. This suggests that the apoptosis-
inhibitory function of PAI-1 exerts through other pathways.
This novel function of PAI-1 is not limited to tumour cells in
vitro. The present findings of the inhibition of apoptosis in
HUVEC and in MCF-10A cells by PAI-1 suggest that this function
is also a physiologic one. Furthermore, apoptosis was induced in
these benign cells by physiologic means, and not by chemothera-
peutic agents.
By inhibiting apoptosis in tumour cells, PAI-1 can potentially
increase the aggressiveness of the tumour, supporting the previous
observations that PAI-1 is a poor prognostic indicator (Foekens et
al, 1994; Kuhn et al, 1994; Pedersen et al, 1994; Sier et al, 1994;
Hofmann et al, 1996; Sugiura et al, 1999). On the other hand,
when PAI-1 expression is increased within tumour cells as a result
of transfection, the tumour invasiveness and metastatic potential is
decreased (Cajot et al, 1990; Alizadeh et al, 1995; Soff et al, 1995).
These two sets of findings are not necessarily in conflict. While the
transfection experiments deal with a high expression of PAI-1 by
the tumour cells, the present results are those of the exogenous
addition of PAI-1 to cells. It shows that PAI-1 when expressed
inside the tumour cells may have different results from those when
PAI-1 is high outside the cells, either added experimentally or
when provided by stromal or supporting cells, such as the tumour
vasculature.
In conclusion, our study demonstrates that the presence of
exogenous PAI-1 can inhibit the apoptotic process. This provides
an explanation why PAI-1 levels of the tumour-bearing host are
associated with a bad prognosis. The decreased cancer invasion
observed in experimental models using PAI-1 deficient transgenic
mice (Bajou et al, 1998) may, at least in part, be explained by an
increased apoptosis consequent to the absence of PAI-1. Together
with these previous observations, our data also indicates that
suppression of PAI-1 activity may have beneficial effects in cancer
treatment.
Effect of PAI-1 on apoptosis 1707
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Figure 9 (A) The lack of effect of uPA/PAI-1-stab complex on spontaneous
and CPT-induced apoptosis in HL-60 cells. uPA and PAI-1-stab were allowed
to form a complex at 37°C for 30 min. Control experiments (open bars) were
performed without treatment of PAI-1-stab or uPA/PAI-1-stab complex. There
was a significant difference between cells with and without PAI-1-stab
treatment (shaded bars) for spontaneous and CPT-induced apoptosis. 
(*P < 0.01, n = 4). However, 20 ng ml–1 of uPA/PAI-1-stab complex (solid bars)
showed no inhibition of apoptosis. (B) The lack of effect of antibodies to
domain 1 (anti-D1) or domain 2 (anti-D2) of uPAR on the apoptosis-inhibiting
function of PAI-1-stab. After being incubated with 18 mg ml–1 antibodies for 
1 h, the cells were treated with 20 ng ml–1 PAI-1-stab for 2 h (*P < 0.005, n = 5)1708 HC Kwaan et al
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